louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05425368: Comparing Two Indirect Pulp Capping Agents for Permanent Teeth
Official title: Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Mineral Trioxide Aggregate as Indirect Pulp Capping Agents in Deeply Carious Young Permanent Molars Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Deep Caries
Keywords: partial caries removal
indirect pulp capping
fluorides
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-06-21
Enrollment: 30
Sex: ALL
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim of the study:

To evaluate clinical and radiographic success rates of silver diamine fluoride versus mineral trioxide aggregate as indirect pulp capping agents in deeply carious young first permanent molars.

Detailed description: Indirect pulp treatment has become a common maneuver in vital pulp therapy in recent years and is a procedure performed in teeth with deep carious lesions approximating the pulp but without any signs or symptoms of irreversible pulpal changes.

Silver Diamine Fluoride is used to arrest caries lesions in primary teeth but according to the AAPD,2021 more research is needed on the use of SDF to arrest caries lesions in permanent teeth.

Eligibility criteria: Inclusion Criteria:

* Patient and parent showing cooperation and compliance.
* Children 9-14 years old
* Vital deeply carious young first permanent molar(s) with complete root formation
* Asymptomatic teeth or without clinical symptoms of spontaneous pain
* Both genders will be included.

Exclusion Criteria:

* Children unable to return for recall visits.
* Any clinical signs of irreversible pulpitis or pulp necrosis (spontaneous pain, pain on percussion, abscess, sinus).
* Any radiographic sign of irreversible pulp pathologies or pulp necrosis (periapical radiolucency, internal or external root resorption)

Primary outcomes:
measure: Dentin bridge formation
timeFrame: 6 months
Secondary outcomes:
measure: Postoperative pain
timeFrame: 1 week
measure: Absence of sinus or fistula
timeFrame: 3 months
measure: Absence of sinus or fistula
timeFrame: 6 months
measure: radiographic success
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Professor of Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Cairo University
name: Manal Ahmed El Sayed
role: PRINCIPAL_INVESTIGATOR
affiliation: Professor of Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Cairo University
name: Randa Youssef Abd Al Gawad
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01217268: Use of Telemedicine in Collaboration Between a Psychogeriatric Unit and Nursing Homes
Official title: Use of Telemedicine in Collaboration Between a Psychogeriatric Unit and Nursing
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Dementia
Behavioural Disorders
Lead sponsor: Sykehuset Innlandet HF
Sponsor class: OTHER
Collaborators: name: Norwegian Department of Health and Social Affairs
First posted: 2010-10-08
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators want to evaluate the use of video-conference in the collaboration between the investigators psychogeriatric department and nursing homes. The study aim is to give supervision on a regular basis to the caregivers on a special care unit for patients with dementia with behavioural disturbances during a period of half a year. The investigators want to investigate the impact on caregivers and patients by applying certain tests at baseline, during the intervention and half a year after the intervention.


Eligibility criteria: Inclusion Criteria:

* Being resident in a special care unit for persons with dementia

Exclusion Criteria:

* Shorter stay than four weeks before inclusion
* terminally ill

Primary outcomes:
measure: Neuropsychiatric inventory - nursing home version (NPI-NH)
timeFrame: week 48
Secondary outcomes:
measure: Person-centered Care Assessment Tool (P-CAT) Person centered care assessment tool (P-CAT)
timeFrame: week 48
Other outcomes:
Locations:
city: Reinsvoll
country: Norway
facility: Sykehuset Innlandet HF
Study officials:
affiliation: SykehusetInnlandet, Norway
name: Oskar H Sommer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02278068: COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy
Official title: A First in Human (FIH) Clinical Study to Assess Safety and Performance of Hepatic Sympathetic Denervation for Treatment of Inadequately Controlled Type 2 Diabetic Subjects on Oral Antihyperglycemic Agents.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Endocrine, Nutritional and Metabolic Diseases (E00-E89)
Keywords: Type 2 diabetes
Lead sponsor: Metavention
Sponsor class: INDUSTRY
First posted: 2014-10-29
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to collect information about a new treatment for Type 2 Diabetes Mellitus (T2DM), using a medical device called the Metabolic Neuromodulation System which is intended to help regulate blood glucose levels in patients whose (T2DM) is not well controlled despite treatment with multiple medications. The medical device delivers low-level radiofrequency energy through the wall of the blood vessel to the liver to disrupt the nerves that lead to the liver. Previous research has shown that disrupting these nerves may lead to a lowering of blood sugar levels.

Detailed description: Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.

Eligibility criteria: Inclusion Criteria:

* Age 18-65 years
* Uncontrolled T2DM, as evidenced by HbA1c levels, on a consistent oral anti-hyperglycemic drug regimen of at least two different drug classes
* Documented status of stable lifestyle modifications

Exclusion Criteria:

* Diagnosed type 1 diabetes mellitus
* History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy
* Estimated glomerular filtration rate (GFR) \< 60mL/min/1.73m2

Primary outcomes:
measure: Primary Safety Outcome as assessed by Incidence of serious adverse device effects
timeFrame: 180 day follow-up
Secondary outcomes:
measure: Device and Procedural success
timeFrame: intra operative
measure: Glycemic control
timeFrame: 180 day and 365 day follow-up
measure: Laboratory Assessments/Cardiometabolic Changes
timeFrame: 180 day follow up
measure: Adverse Event Rate
timeFrame: 365 day follow up
Other outcomes:
Locations:
city: Auckland
country: New Zealand
facility: Auckland City Hospital
city: Auckland
country: New Zealand
facility: Middlemore Hospital
city: Auckland
country: New Zealand
facility: North Shore Hospital
city: Christchurch
country: New Zealand
facility: Christchurch Hospital
city: Dunedin
country: New Zealand
facility: Dunedin Hospital
city: Wellington
country: New Zealand
facility: Wellington Hospital
Study officials:
affiliation: Auckland City Hospital
name: Mark Webster, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04351568: Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;
Official title: Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services; During the Period of 19 Covid Pandemics
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Evaluating the Effect of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-04-17
Enrollment: 874
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: medical and non medical personel

Brief summary: integrating social media into medicine has obvious potential to improve patient care and trust in the profession, in part by meeting patients "where they are," i.e., online, at the same time carries a greater risk in terms of legal, ethical, and professional aspects. Therefore, physicians and medical students using social media should pay attention to the ethical sensitivity in their relationships with patients .it also raises a number of ethical issues including protecting patient and physician privacy; setting appropriate online boundaries; and delineating personal and professional identities among others during covid 19 pandemics


Eligibility criteria: Inclusion Criteria:

1. adult aged 18 years to 60 years
2. medical personel graduated from egyptian faculty of medicine.
3. non medical personel live in egypt

Exclusion Criteria:

1. personel less than 18 years old .
2. medical personel not graduated from egyptian faculty of medicine.
3. non medical personel live outside egypt

Primary outcomes:
measure: to evaluate the effect of social media usage in medical practice during covid 19 epidemic
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut
Study officials:
References:
Clinical trial NCT05885568: Validation of the Transport of Biological Material by Drone
Official title: Validation of the Conditions of Transport of Biological Material by Drone Within the "Groupement Hospitalier de Territoire Somme Littoral Sud"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Drone Transport
Biological Samples
Unmanned Aerial System
Keywords: drone transport
biological samples
unmanned aerial system
UAS
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
Collaborators: name: Centre Hospitalier de l'Arrondissement de Montreuil-sur-mer
First posted: 2023-06-02
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The Hospital Group of Territory Somme Littoral Sud, through its biology sector and in partnership with the company DELIVRONE, aims to engage in the experiment of transporting biological samples by means of a drone platform. Transport by air will be between the CHAM, the Abbeville Hospital and the CHU Amiens-Picardie by flying as much as possible over the waterways via the Somme. With a flight speed of around 100km/h at an altitude between 80 and 120 m, drones will be able to connect sites in less than an hour by transporting packages between 2 and 3 kg. Powered by propellers connected to rechargeable batteries, these drones do not emit CO2. This type of transport has not been validated in France by measuring the analytical impact of transport constraints for medical biology, and has never been evaluated according to the criteria of ISO 15189 standard allowing the certification of medical biology laboratories. Validation steps of this transportation method are therefore necessary on pathological samples prior to routine use.

The aim of the project is to validate the transport of biological samples by drone under defined flight conditions between CHAM and CHU Amiens-Picardie


Eligibility criteria: Inclusion Criteria:

* participants of legal age
* No contraindication to blood collection
* Voluntary
* informed and consenting participants

Exclusion Criteria:

* Impossible to collect sufficient blood volume
* Refusal to participate in the study

Primary outcomes:
measure: Variation of destination arrival between both transportation types
timeFrame: one hour
measure: Variation of sample temperature during transportation
timeFrame: one hour
measure: Variation of sample allotted time after both transportation types
timeFrame: one hour
measure: Variation of sample degradation after both transportation types
timeFrame: one hour
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT01741168: Brace Versus No Brace for the Treatment of Thoracolumbar Burst Fractures Without Neurologic Injury
Official title: TLSO Versus No Orthosis for the Treatment of Thoracolumbar Burst Fractures Without Neurologic Injury: A Multicenter Prospective Randomized Equivalence Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thoracolumbar Burst Fractures Without Neurologic Deficit
Lead sponsor: The London Spine Centre
Sponsor class: OTHER
First posted: 2012-12-04
Enrollment: 97
Sex: ALL
Minimum age (years): 16
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Braces have been used o treat stable (not requiring surgery) burst fractures with much success. Recently questions have been raised in regards to the importance of the brace. Some studies have results that suggest a brace is not important in having a good outcome. However, this has never been proven. This study is being conducted to see whether or not wearing a brace is important to having a good outcome.

Detailed description: The purpose of this study is to prospectively compare the outcome between patients randomly assigned to a thoracolumbosacral orthosis (TLSO) treatment group or no orthosis (NO) treatment group, for the management of an acute AO type A3 thoracolumbar fracture.

Eligibility criteria: Inclusion Criteria:

* AO A3 burst fracture between T10 and L3 with associated kyphotic deformity \<35 degrees
* neurologically intact or isolated nerve root deficit
* age 16-60 years
* enrollment within 3 days of injury

Exclusion Criteria:

* neurological deficit
* can not comply with brace wearing (pregnancy/body mass index \>40)
* mobilized with or without a brace prior to recruitment
* suffered a pathologic or open fracture
* alcohol or drug abusers
* had previous injury or surgery to the thoracolumbar region
* unable to complete the questionnaires

Primary outcomes:
measure: Roland Morris Disability Questionnaire
timeFrame: 3 months post fracture
Secondary outcomes:
measure: SF-36 physical component summary score
timeFrame: enrollment, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, 2years
measure: SF-36 mental component summary score
timeFrame: enrollment, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, 2 years
measure: VAS pain score
timeFrame: enrollment, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months
measure: Satisfaction with Treatment
timeFrame: enrollment, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months
Other outcomes:
Locations:
city: London
country: Canada
facility: London Spine Centre
state: Ontario
Study officials:
References:
Clinical trial NCT06557668: Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer
Official title: Clinical Outcomes of Treatment With Immunomodulator Plus Standard Anti-cancer Therapies for Patients With Colorectal Cancer: A Retrospective Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Colorectal Cancer
Keywords: Colorectal Cancer
Astragalus Polysaccharides
Survival
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2024-08-16
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Colorectal Cancer

Brief summary: This study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment, both with and without an immunomodulator.

Detailed description: Colorectal cancer (CRC) is the third most common cancer worldwide. The clinical outcomes from CRC treatments are often unsatisfactory for the majority of patients. The tumor microenvironment (TME) plays an important role to regulate tumor growth, progression, and metastasis and can limit the efficacy of cancer therapies. Therefore, targeting TME could provide an efficient approach for cancer treatment.

Astragalus Polysaccharide Injection, an immunomodulator, which can stimulate medullary hematopoiesis and enhance immune function. It also can modulate TME. Astragalus Polysaccharide Injection has been approved as a prescription drug for alleviating cancer-related fatigue by the Taiwan Food and Drug Administration (TFDA).

In this retrospective study, we will collect clinical data and survival status of colorectal cancer patients undergoing anti-cancer treatment from their medical records with and without immunomodulator, Astragalus polysaccharide Injection. It can be used to understand the possible clinical benefit of immunomodulator plus anti-cancer therapies for patients with colorectal cancer, and physicians can refer to these results to give patients the suitable treatment recommendations.

Eligibility criteria: Inclusion Criteria:

* Aged 20 years and older.
* Patients who have been given a diagnosis of colorectal cancer.
* Patients had previously initiated anti-cancer therapies between January 1, 2020, and Apr 30, 2024.

Exclusion Criteria:

* None

Primary outcomes:
measure: Overall survival
timeFrame: From the initial treatment until April 2024
Secondary outcomes:
measure: Progress free survival
timeFrame: From the initial treatment until April 2024
measure: Tumor response
timeFrame: From the initial treatment until April 2024
Other outcomes:
Locations:
city: Taichung City
country: Taiwan
facility: Chung-Shan Medical University Hospital
city: Taichung City
country: Taiwan
facility: Taichung Veterans General Hospital
Study officials:
References:
Clinical trial NCT05507268: Predictive Nomogram for Postoperative Acute Kidney Injury in Older Patients Undergoing Noncardiac Surgery
Official title: Predictive Nomogram for Postoperative Acute Kidney Injury in Older Patients Undergoing Noncardiac Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Postoperative Acute Kidney Injury
Keywords: prediction model
nomogram
older
noncardiac surgery
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2022-08-18
Enrollment: 50000
Sex: ALL
Minimum age (years): 65
Maximum age (years): 120
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Older patients (aged ≥ 65 years) undergoing noncardiac surgery from 2012-2019

Brief summary: Postoperative acute kidney injury is associated increased risk of morbidity and mortality. Older patients are at high risk of developing postoperative acute kidney injury. However, the incidence and associations of postoperative acute kidney injury in older patients are not well understood. This study aims to develop and validate a predictive nomogram for postoperative acute kidney injury in older patients undergoing noncardiac surgery.

Detailed description: Postoperative acute kidney injury (AKI) affects approximately 2% to 40% of patients undergoing cardiac and major noncardiac surgeries.

Older patients are more susceptible to renal impairment than younger patients. However, the incidence and associations of AKI in older patients are rarely understood.

Generally, in-depth knowledge of risk factors and thus able to identify patients at high risk to develop postoperative AKI is essential to optimize perioperative prevention and protection strategies.

In this retrospective study, the investigators intend to develop and validate a predictive model for postoperative using the identified risk factors.

The primary outcome is postoperative AKI, which according to the Kidney Disease: Improving Global Outcomes (KDIGO) criterion, is defined as an absolute increase in serum creatinine of 0.3 mg/dL within 48 hours or a 1.5-fold increase from preoperative baseline within 7 days after surgery.

Eligibility criteria: Inclusion Criteria:

* Patients aged 65 years and older

Exclusion Criteria:

* Emergency operation
* Cardiac surgery
* Incomplete data
* Incomplete data
* Local anesthesia
* Preoperative renal failure or requirement for dialysis

Primary outcomes:
measure: acute kidney injury
timeFrame: 7 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: the First Medical Center of Chinese PLA General Hospital
state: Beijing
Study officials:
affiliation: The First Medical Center of Chinese PLA General Hospital
name: Weidong Mi, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00179868: C-Reactive Protein as a Predictor of Stem Cell Transplant Complications
Official title: C-Reactive Protein As a Predictor of Major Transplant Complications in Pediatric Stem Cell Transplant Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Leukemia
Stem Cell Transplantation
Keywords: cancer
leukemia
stem cell transplant
complications
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 70
Sex: ALL
Minimum age (years): 6
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children undergoing a stem cell transplant

Brief summary: The purpose of this study is to determine if C-Reactive Protein levels are predictive for complications post transplant.


Eligibility criteria: Inclusion Criteria:

* Age 6 months to 20 years
* Patient undergoing a stem cell transplant (allogeneic, syngeneic, or autologous) at Childrens' Memorial Hospital
* IRB approved informed consent (and assent for children age 12-17)

Primary outcomes:
measure: To determine whether quantitative c-reactive protein measurements can predict major morbidity and mortality in pediatric stem cell transplant patients.
timeFrame: To day +100 post transplant
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Children's Memorial Hospital
state: Illinois
Study officials:
affiliation: Ann & Robert H Lurie Children's Hospital of Chicago
name: Morris Kletzel, MD
role: PRINCIPAL_INVESTIGATOR
References: